Compugen to Present Experimental Data of its MCP-1 Antagonist Candidate at GTCBio's Cytokines and Inflammation Conference
29 Enero 2007 - 6:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) announced today that it will present
experimental results for its previously disclosed CGEN-54, an MCP-1
antagonist therapeutic candidate, at GTCBio�s 5th Cytokines and
Inflammation Conference (January 29-30, 2007, Breckenridge,
Colorado). Compugen�s CGEN-54 is a truncated variant of MCP-1 that
is encoded by a novel splice variant, and the results to be
presented at the Conference demonstrate the molecule�s ability to
inhibit the MCP-1/CCR2 pathway both in-vitro and in-vivo. In cell
culture, CGEN-54 strongly inhibited MCP-1-induced monocytes
migration, whereas in-vivo, CGEN-54 was effective in reducing
macrophage infiltration in a mouse model of peritoneal
inflammation. CGEN-54 was one of three therapeutic candidates for
which Compugen announced in late 2006 the discovery and
demonstration of functional activity. This molecule, and splice
variants of c-Met receptor and ANP hormone, had initially been
predicted in silico utilizing the Company�s first therapeutics
discovery engine, based on Compugen�s long-term leadership in the
field of alternative splicing. MCP-1 (Monocyte Chemoattractant
Protein 1, also named CCL2) belongs to the CC chemokines family and
is induced in response to various inflammatory stimuli. Binding of
MCP-1 to its cognate receptor, CCR2, leads to recruitment of
specialized immune cells into the site of inflammation, resulting
in tissue destruction. The inhibition of the MCP-1/CCR2 pathway
represents a promising target to effectively modulate disease
progression in chronic inflammatory diseases, such as multiple
sclerosis. About Compugen Compugen�s mission is to be the world
leader in the discovery and licensing of product candidates to the
drug and diagnostic industry. The Company�s powerful discovery
engines enable the predictive discovery of numerous potential
therapeutics and diagnostic biomarkers. This capability results
from the Company�s decade-long pioneering efforts in the deeper
understanding of important biological phenomena at the molecular
level through the incorporation of ideas and methods from
mathematics, computer science and physics into biology, chemistry
and medicine. To date, Compugen�s diagnostic and therapeutic
product discovery efforts and its initial discovery engines have
focused mainly within the areas of cancer, immune-related and
cardiovascular diseases. (should anything be added due to Medarex)
The Company's primary commercialization pathway for its therapeutic
and diagnostic product candidates is to enter into milestone and
revenue sharing out-licensing and joint development agreements with
leading companies. Compugen has established an agricultural
biotechnology affiliate � Evogene, and a small-molecule drug
discovery affiliate � Keddem Bioscience. For additional
information, please visit Compugen's corporate Website at
www.cgen.com.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024